We are adding the following to our August recommended list.

Since September recommendations will be coming out next weekend We are adding just one credit spread in the following issue today.

GENZ - Genzyme Corporation operates as a biotechnology company worldwide. It focuses on rare genetic disease disorders, renal diseases, orthopaedics, cancers, transplant and immune diseases, and diagnostic and predictive testing areas. The companyÂ’s Genetic Diseases segment manufactures and distributes Cerezyme for the treatment of Gaucher disease; Fabrazyme for the treatment of Fabry disease; Myozyme for the treatment of Pompe disease; Aldurazyme for the treatment of Mucopolysaccharidosis I; and Elaprase for the treatment of Mucopolysaccharidosis II. Its Cardiometabolic and Renal segment offers Renagel and Renvela for the control of serum phosphorus in patients with chronic kidney disease on dialysis; Hectorol for the treatment of secondary hyperparathyroidism; and Thyrogen, an adjunctive diagnostic agent used in the follow-up of patients with well-differentiated thyroid cancer.

We are recommending the following specific credit spread.

Put credit spread = bullish put spread.


The following issue is a supplement ETF trade you might consider in your search for profitable option trades. This particular trade is a volatility traded index. As with any investment, you must decide if this selection meets your criteria for a potential play. Only you can know what strategies and positions are suitable for your experience level, risk-reward tolerance and individual outlook. There will be no commentary or analysis offered on this position, nor will it be included in the MCM Portfolio.

PLEASE NOTE:MCM SEPT 2010 RECOMMENATIONS will start next weekend.